{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:36:49Z","timestamp":1760240209907,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>In clinical trials, a sofosbuvir\/velpatasvir (SOF\/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic patients with portal hypertension are available. The aim of this study was to assess the effectiveness of SOF\/VEL in GT3 cirrhotics with portal hypertension. Patients with GT3 and advanced cirrhosis were treated for 12 weeks with SOF\/VEL without ribavirin at five different centers in Italy from June 2017 to August 2018 and their SVR12 was assessed. Of the 227 GT3 cirrhotics evaluated, 205 met the inclusion criteria and 111 had transient elastography results \u226520 KPa. SVR12 was 97.6% (95% CI 94.4\u201398.9), rates were 99.1% (95% CI 95.7\u201399.8) in patients with \u226520 KPa and 95.8% (95% CI 89.5\u201398.3) in those with &lt;20 KPa (p = 0.18). Analyzed by presence of esophageal varices, the SVR12 rates were 98.4% (95% CI 91.4\u201399.7) and 97.1% (95% CI 92.9\u201398.9) in patients without and with varices, respectively (p = 1.0). In real life, SOF\/VEL GT3 cirrhotic patients with evidence of portal hypertension can achieve SVR12 levels comparable to those of patients without portal hypertension. These SVR12 rates are similar to what is reported in compensated cirrhosis treated within clinical trials.<\/jats:p>","DOI":"10.3390\/cells8040313","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T11:36:01Z","timestamp":1554464161000},"page":"313","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF\/VEL without Ribavirin: A Nation-Wide Cohort Study"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-3555","authenticated-orcid":false,"given":"Alessandra","family":"Mangia","sequence":"first","affiliation":[{"name":"Liver Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cenderello","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Ospedale \u201cGalliera\u201d, 16128 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Verucchi","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Universit\u00e0 di Bologna, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Piazzolla","sequence":"additional","affiliation":[{"name":"Liver Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Liver Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Santoro","sequence":"additional","affiliation":[{"name":"Liver Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Squillante","sequence":"additional","affiliation":[{"name":"Liver Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Orlandini","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, University of Parma, 43125 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Minisini","sequence":"additional","affiliation":[{"name":"Internal Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Universit\u00e0 di Torino, 10124 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"Vermehren","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mangia, A., Piazzolla, V., Losappio, R., Giannelli, A., Visaggi, E., Bacca, D., Sogari, F., Potenza, D., Santoro, R., and Carraturo, I. (2019). High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir\/Velpatasvir (SOF\/VEL) combination for 12 weeks without Ribavirin (RBV). PLoS ONE, accepted.","DOI":"10.1016\/S0168-8278(18)30763-3"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance- associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"Vermehren","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mangia, A., Losappio, R., Cenderello, G., Potenza, D., Mazzola, M., De Stefano, G., Terreni, N., Copetti, M., Minerva, N., and Piazzola, V. (2018). Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis\/cirrhosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200568"},{"key":"ref_8","unstructured":"Fagiuoli, S., Agarwall, K., Mangia, A., Shafran, S.D., Wedemeyer, H., Terrault, N.A., Feld, J.J., Turnes, J., Buggisch, P., and Perez, F. (2018, January 8\u201313). Effectiveness of Sofosbuvir\/Velpatasvir for 12 weeks in HCV Genotype 3 patients with compensated cirrhosis in clinical practice cohorts from around the world. Proceedings of the Liver Meeting, San Francisco, CA, USA."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.06.004","article-title":"Revising consensus in portal hyper- tension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"53","author":"Faculty","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1056\/NEJMoa1512614","article-title":"ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies amelio- rates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral antiviral therapy on HVPG and systemic haemodinamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL recommendations on the treatment of hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_14","unstructured":"AASLD\/IDSA (2018, March 15). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: https:\/\/hcvguidelines.org."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of Sofosbuvir and Velpatasvir with and without Ribavirin in patients with HCV genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients","volume":"39","author":"Pasta","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: A systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_18","unstructured":"Robert, S., Buti, M., Foster, G., Calleja, J.L., Sood, A., Isakov, V.A., Weiland, O., Stamm, L.M., Ni, L., and Svarovskaia, E. (2018, January 8\u201313). Sofosbuvir\/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: An Integrated Analysis of Phase 2 and Phase 3 Clinical Trials. Proceedings of the Liver Meeting, San Francisco, CA, USA."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/liv.13318","article-title":"Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding","volume":"37","author":"Marot","year":"2017","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Carrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., De Ledinghen, V., Larrey, D., Haour, G., and Bronowicki, J.P. (2019). Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study. Lancet.","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Thaubot, D., Bureau, C., Layese, R., Bourcier, V., Hammouche, M., Cagnot, C., Marcellin, P., Guyader, D., Pol, S., and Larrey, D. (2019). Validation of Baveno VI criteria for screening and surveilance of esophageal varices in patients with compensated cirrhosis and a sustsained response to antiviral therapy. Gastroenterology, in press.","DOI":"10.1053\/j.gastro.2018.11.053"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","unstructured":"Belperio, P., Shahoumian, T., Loomis, T., Mole, L., and Backus, L.I. (2018, January 9\u201313). Real-world Effectiveness of glecaprevir\/pibrentasvir in 1941 patients with hepatitis C genotypes 1 through 4. Proceedings of the Liver Meeting, San Francisco, CA, USA."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hezode, C., Reau, N., Svarovskaia, E., Doehle, B.P., Chodavarapu, K., Dvory-Sobol, H., McNally, J., Osinusi, A., Brainard, D.M., and Miller, M.D. (2016, January 13\u201317). Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir\/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies. Proceedings of the The International Liver Congress, Barcelona, Spain.","DOI":"10.1016\/S0168-8278(16)00629-2"},{"key":"ref_25","unstructured":"World Health Organization (2016, June 01). Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021: Towards Ending Viral Hepatitis. Available online: http:\/\/apps. who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/4\/313\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:43:07Z","timestamp":1760186587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/4\/313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["cells8040313"],"URL":"https:\/\/doi.org\/10.3390\/cells8040313","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2019,4,4]]}}}